This article is more than 5 years old. Information may no longer be current.

pSivida revenue totals $526,000 in second fiscal quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

pSivida reported revenue of $526,000 in its second fiscal quarter compared with $521,000 in the same quarter a year ago, according to a press release.

Net loss was reported at $5.2 million, or $0.18 per share, compared with $4.1 million, or $0.14 per share, in the same quarter of the previous year.

Operating expenses were reported at $5.8 million in the second fiscal quarter compared with $4.6 million a year ago. The increase was attributed to costs of the Medidur clinical development program.

In the first 6 months of the fiscal year, revenue totaled $992,000 compared with $25.8 million in the previous year. The decrease was attributed to a $25 million milestone for the FDA approval of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) earned in the previous year.